OCGN catalyst calendar

Ocugen, Inc.

Upcoming catalysts
4
Cash runway
13.8 months
Cash & investments
$100M
Phase 3 programs
5

Ocugen, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on December 6, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.

Cash runway is approximately 13.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
December 6, 2026 est. Next quarterly earnings (projected) Earnings —
February 12, 2027 A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa Trial Milestone Phase 3
March 15, 2027 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis Trial Milestone Phase 1/Phase 2
July 30, 2028 Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD Trial Milestone Phase 3

Track OCGN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open OCGN in the tracker

Recent history

DateEventTypePhase
September 28, 2026 A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease Trial Milestone Phase 2/Phase 3
September 8, 2026 8-K filed: Reg FD disclosure, Other event Filing —
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 31, 2026 Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) Trial Milestone Phase 1
July 13, 2026 8-K filed: Other event Filing —
June 11, 2026 8-K filed: Other event Filing —
June 3, 2026 8-K filed: Leadership change Corporate —
May 14, 2026 8-K filed: Reg FD disclosure Filing —
May 14, 2026 8-K filed: Leadership change, Other event Corporate —
May 7, 2026 Quarterly results filed (8-K) Earnings —
May 5, 2026 Quarterly results filed (8-K) Earnings —
May 4, 2026 Quarterly results filed (8-K) Earnings —
March 27, 2026 8-K filed: Reg FD disclosure Filing —
March 24, 2026 8-K filed: Reg FD disclosure Filing —
March 20, 2026 8-K filed: Other event Filing —
March 4, 2026 Quarterly results filed (8-K) Earnings —
March 4, 2026 8-K filed: Other event Filing —
February 9, 2026 8-K filed: Leadership change Corporate —
February 3, 2026 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Trial Milestone Phase 1/Phase 2
January 23, 2026 8-K filed: Reg FD disclosure, Other event Filing —
January 21, 2026 8-K filed: Material agreement, Other event Corporate —
January 15, 2026 8-K filed: Other event Filing —
December 18, 2025 8-K filed: Leadership change Corporate —
November 5, 2025 Quarterly results filed (8-K) Earnings —
September 16, 2025 8-K filed: Material agreement Corporate —
September 5, 2025 8-K filed: Material agreement Corporate —
August 11, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 1, 2025 Quarterly results filed (8-K) Earnings —
July 30, 2025 8-K filed: Other event Filing —
July 29, 2025 8-K filed: Other event Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.